CO

Cencora, Inc.

CORHealthcareNASDAQ

Medical Distribution

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$321.33B
+9.3% YoY
Net Income
$1.55B
+3.0% YoY
EBITDA
$3.75B
+11.1% YoY
Free Cash Flow
-$318.2M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 77.5, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 70.5, above 70, stock may be overbought
About Cencora, Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. With a market capitalization of $57.70B, it sits in large-cap territory.

Key stats
Market Cap$57.70B
P/E (TTM)23.15
Fwd P/E14.96
EPS$12.81
Beta0.58
52W Change-0.4%
Dividend Yield0.79%
ROE107.1%
Analysis

The company holds $2.18B in cash, though total debt stands at $15.09B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$318.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 107.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $238.59B (2022) to $321.33B (2025), reflecting a 35% increase over the period.

The relatively low beta of 0.58 suggests COR is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing COR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms